291 related articles for article (PubMed ID: 17935056)
1. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
2. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
3. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate for Diabetic Retinopathy.
Stewart S; Lois N
Asia Pac J Ophthalmol (Phila); 2018; 7(6):422-426. PubMed ID: 30058790
[TBL] [Abstract][Full Text] [Related]
5. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Collins PD; Sattar N
Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate and metabolic syndrome.
Kraja AT; Province MA; Straka RJ; Ordovas JM; Borecki IB; Arnett DK
Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):138-48. PubMed ID: 20406163
[TBL] [Abstract][Full Text] [Related]
7. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
[TBL] [Abstract][Full Text] [Related]
8. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
van Stee MF; de Graaf AA; Groen AK
Cardiovasc Diabetol; 2018 Jun; 17(1):94. PubMed ID: 29960584
[TBL] [Abstract][Full Text] [Related]
9. Management of Lipid Abnormalities in Patients with Diabetes.
Sillars A; Sattar N
Curr Cardiol Rep; 2019 Nov; 21(11):147. PubMed ID: 31758270
[TBL] [Abstract][Full Text] [Related]
10. The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.
Malur P; Menezes A; DiNicolantonio JJ; O'Keefe JH; Lavie CJ
Mo Med; 2017; 114(6):464-471. PubMed ID: 30228666
[TBL] [Abstract][Full Text] [Related]
11. Uridine prevents fenofibrate-induced fatty liver.
Le TT; Urasaki Y; Pizzorno G
PLoS One; 2014; 9(1):e87179. PubMed ID: 24475249
[TBL] [Abstract][Full Text] [Related]
12. Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Rotroff DM; Pijut SS; Marvel SW; Jack JR; Havener TM; Pujol A; Schluter A; Graf GA; Ginsberg HN; Shah HS; Gao H; Morieri ML; Doria A; Mychaleckyi JC; McLeod HL; Buse JB; Wagner MJ; Motsinger-Reif AA;
Clin Pharmacol Ther; 2018 Apr; 103(4):712-721. PubMed ID: 28736931
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
Tziomalos K; Athyros VG
Int J Nanomedicine; 2006; 1(2):129-47. PubMed ID: 17722529
[TBL] [Abstract][Full Text] [Related]
14. Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes.
Lan NSR; Hong RSY; Ryan C; Jenkins AJ; Fegan PG
Prim Care Diabetes; 2023 Oct; 17(5):526-528. PubMed ID: 37532667
[TBL] [Abstract][Full Text] [Related]
15. Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.
Jenkins AJ; O'Connell RL; Januszewski AS; Webster AC; M E Davis T; Jardine MJ; Scott RS; Taskinen MR; Keech AC;
Diabetes Res Clin Pract; 2024 Apr; 210():111612. PubMed ID: 38479447
[TBL] [Abstract][Full Text] [Related]
16. Use of fibrates in the metabolic syndrome: A review.
Shipman KE; Strange RC; Ramachandran S
World J Diabetes; 2016 Mar; 7(5):74-88. PubMed ID: 26981181
[TBL] [Abstract][Full Text] [Related]
17. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
19. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.
Vlase L; Popa A; Muntean D; Leucuta SE
Arzneimittelforschung; 2010; 60(9):560-3. PubMed ID: 21117499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
